These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28387109)

  • 41. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety of edoxaban for treating atrial fibrillation.
    Hammwöhner M; Goette A
    Expert Opin Drug Saf; 2017 Nov; 16(11):1295-1303. PubMed ID: 28862063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):409-16. PubMed ID: 24607764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Chen J; Zhuang X; Long M; Su C; Wang L
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
    Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
    Weitz JI; Eikelboom J
    Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
    Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study.
    Niebecker R; Jönsson S; Karlsson MO; Miller R; Nyberg J; Krekels EH; Simonsson US
    Br J Clin Pharmacol; 2015 Dec; 80(6):1374-87. PubMed ID: 26218447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.
    van Ommen CH; Albisetti M; Chan AK; Estepp J; Jaffray J; Kenet G; Young G; Dave J; Grosso MA; Duggal A
    Res Pract Thromb Haemost; 2020 Jul; 4(5):886-892. PubMed ID: 32685899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.
    Fuji T; Fujita S; Kawai Y; Abe Y; Kimura T; Fukuzawa M; Abe K; Tachibana S
    Thromb J; 2015; 13(1):6. PubMed ID: 25653574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin.
    Bavalia R; Bistervels IM; Boersma WG; Quere I; Brisot D; Falvo N; Stephan D; Couturaud F; Schellong S; Beyer-Westendorf J; Montaclair K; Ghanima W; Ten Wolde M; Coppens M; Ferrari E; Sanchez O; Carroll P; Roy PM; Kahn SR; Meijer K; Birocchi S; Kovacs MJ; Hugman A; Ten Cate H; Wik H; Pernod G; Sevestre-Pietri MA; Grosso MA; Shi M; Lin Y; Hutten BA; Verhamme P; Middeldorp S;
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12566. PubMed ID: 34278193
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.